Employees: 3,049
Size Integral Diagnostics (IDX.AX) is an Australia Health Care company (Medical/Nursing Services) with a market value of $413M, the 278th largest of 317 Australia companies the cockpit tracks. Shares closed at A$1.62 on 18 Nov 2026.
Performance Over six months the shares fell 21.9%, against -3.5% for the median peer and +1.2% for the Australia market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 25.7% over the last twelve months (peer median +5.1%); the operating margin is 8.7% (peer median 8.0%).
Valuation It trades at 14.7× forward earnings against a peer median of 17.6× (5th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.0 points below its cost of capital (6.8% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | A$789M | A$789M | A$627M | A$470M | A$440M |
| Revenue growth | — | +26% | +34% | +7% | — |
| Gross profit | A$169M | A$169M | A$136M | A$104M | A$96.4M |
| EBITDA | A$143M | A$142M | A$114M | A$89.0M | A$82.0M |
| Net income | A$21.9M | A$21.9M | A$2.69M | -A$60.7M | A$25.0M |
| Free cash flow | A$45.6M | A$45.6M | A$14.0M | A$42.3M | A$23.1M |
| Capital expenditure | A$49.6M | A$49.6M | A$59.8M | A$23.9M | A$44.0M |
| Total debt | n/a | A$597M | A$585M | A$358M | A$365M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IDX.AX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.2% | -6.8% | 4th lowest of 21 |
| 6-month return | -21.9% | -3.5% | 3rd lowest of 20 |
| Distance from 52-week high | -40.0% | -26.3% | 6th lowest of 21 |
| Revenue growth (TTM) | +25.7% | +5.1% | 6th highest of 21 |
| Operating margin | 8.7% | 8.0% | 10th highest of 21 |
| Forward P/E | 14.7× | 17.6× | 5th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | 7.8% | 5.6% | 7th most demanding of 17 |
| Growth delivered (Del g) | +17.7% | +15.4% | 8th highest of 17 |
| Hurdle (Req g minus delivered) | -9.9 pp | -13.8 pp | 8th most demanding of 17 |
| ROIC minus cost of capital | -3.0 pp | -0.3 pp | 9th lowest of 20 |
| EV / EBITDA | 8.2× | 9.8× | 5th cheapest of 13 |
| Net debt / EBITDA | 3.8× | 1.5× | 2nd most indebted of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 14.7× | 7.8% | +17.7% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 17.8× | 4.3% | +2.6% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 17.4× | 7.3% | +42.6% |
| ADICON 9860.HK | Hong Kong | $393M | +5% | +1% | 4% | 24.6× | 12.3% | -1.5% |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 86.3× | n/a | n/a |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | n/a | n/a | n/a |
| M1 Kliniken M12.DE | Germany | $368M | +1% | -28% | 13% | 16.4× | -5.3% | +17.9% |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $352M | +17% | 0% | -2% | n/a | -14.9% | +9.6% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | n/a | 5.9% | +3.2% |
| Tellgen 300642.SZ | China | $328M | -11% | +5% | 8% | n/a | 18.8% | -5.8% |
| Oncology Institute STLN | United States | $326M | n/a | +35% | -3% | n/a | 5.4% | +21.8% |
| NIOX NIOX.L | United Kingdom | $325M | +3% | +3% | 22% | 19.8× | 3.4% | +15.3% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | n/a | n/a | n/a |
| Auna AUNA | United States | $309M | -5% | +17% | 13% | 4.1× | -10.7% | +24.4% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $309M | -4% | +5% | 31% | 9.2× | -13.8% | +15.4% |
| Dr. Agarwal'S Eye Hospital DRAGARWQ.NS | India | $292M | +14% | +20% | 21% | n/a | 19.6% | +27.5% |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 10.1× | 10.1% | +94.5% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | n/a | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 48.8× | 36.6% | +31.6% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 5.9× | -19.6% | -4.0% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 23.1× | 17.8% | +12.4% |